RGTA® technology and more specifically the ophtalmic device Cacicol20® significantly improve the healing of corneal lesion. Initially, patients have been treated with RGTA® for chronic and persistent injuries in the cornea as documented by numerous clinical cases and on-going studies (for review ). Importantly, over 5000 treated patients were not responsive to conventional therapies and no side effects were caused by the RGTA® application after 5 years of use.
Indeed, RGTA® are used to treat neurotrophic keratitis which is a rare degenerative disease affecting the corneal epithelium and associated with impairment of corneal sensation. This disease is characterized by poor corneal healing and the changes in the corneal epithelium range from superficial punctate keratopathy to persistent epithelial defects and ulcers, possibly developing into stromal melting and corneal perforation. It is mostly caused by herpetic keratitis, chemical and physical injuries, topical drug toxicity, irradiation, diabetes and neurosurgical procedures.
Several studies including a large number of patients suffering from resistant corneal neurotrophic ulcers and keratitis show that application of RGTA® leads to complete healing in approximately 75% of the cases as shown by the successful closure of the neutrotrophic epithelial defects or the decreased ulcer area. No relapse was observed upon the treatment and no side effects were reported [2, 3,4, 5 & 6]. However, response to RGTA® treatment is linked to the access to the extracellular matrix and in many cases these chronic corneal lesions are not easily accessible as they are covered by bacteria and an invisible biofilm. Mecanichal elimination of the biofilm improves the chances of success as shown at ARVO meeting 2017 .
The number of cases with positive outcomes is now increasing, extending to association with bandage contact lens , with limbal allograft in advanced limbal deficiency ,with a topical corticosteroid, antibiotics or indication. Such as corneal perforation associated with Sjorgen’s disease [10 & work in progress] and Cogan’s epithelial dystrophy .
Furthermore, RGTA® have proven highly effective when combined with other therapeutic techniques. Following treatment with crosslinking agents in keratoconus, application of RGTA resulted in an accelerated cell regeneration and repopularization of stroma thus preventing the massive cellular damage caused by the cross-linking [12, 13]. A first randomized controlled trial was published demonstrating that RGTA treatment was significantly increasing the speed of re-epitheliazisation and healing . Several trials are ongoing.
Similarly to patients treated for skins lesions, patients noted significant pain relief associated with RGTA treatment for their corneal injuries underlining the important role of RGTA® in patients quality of life [3, 13].
Resistant to all treatment of the cornea
Observation: Reduction in the size of the ulcer and a subjective dimished discomfort
3-year-follw ip – 1 drop/week – the ulcer did not reopen
Progressive keratoconus after epi-off accelerated CXL
Representative results of a study of 60 patients with progressive keratoconus after epi-off accelerated corneal cross-linking.
2-3 days treatment with Cacicol20®
Observations: 83.3% of eyes treated exhibited complete healing, reduction in ocular pain, burning and, photophobia
1-Barritault, D., Gilbert-Sirieix, M., Rice, K.L., Siñeriz, F., Papy-Garcia, D., Baudouin, C., Desgranges, P., Zakine, G., Saffar, J.-L., and van Neck, J. (2016). RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients. Glycoconjugate Journal - PDF
2- Pison, A., Feumi, C., and Bourges, J.-L. (2014). Cicatrisation d’un ulcère de cornée neurotrophique résistant par thérapie matricielle. Journal Français d’Ophtalmologie 37, e101–e104. - PDF
3-Chebbi, C.K., Kichenin, K., Amar, N., Nourry, H., Warnet, J.M., Barritault, D., and Baudouin, C. (2008). [Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy]. J Fr Ophtalmol 31, 465–471. - PDF
4- De Monchy, I., Labbé, A., Pogorzalek, N., Gendron, G., M’Garrech, M., Kaswin, G., and Labetoulle, M. (2012). [Management of herpes zoster neurotrophic ulcer using a new matrix therapy agent (RGTA): A case report]. J Fr Ophtalmol 35, 187.e1-6. - PDF
5- Aifa, A., Gueudry, J., Portmann, A., Delcampe, A., and Muraine, M. (2012). Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers. Invest. Ophthalmol. Vis. Sci. 53, 8181–8185. - PDF
6- Hughes, L., Lockington, D., Mantry, S., and Ramaesh, K. (2015). Novel matrix ReGeneraTing Agent promotes rapid corneal wound healing. Clin. Experiment. Ophthalmol. 43, 391–392. - PDF
7- Lazreg, S. and Renault, D. The use of corneal scrubbing associated with matrix therapy in the treatment of chronic ulcers. Arvo 2017 abstract 1399. - PDF
8- Kymionis, G.D., Liakopoulos, D.A., Grentzelos, M.A., Diakonis, V.F., Klados, N.E., Tsoulnaras, K.I., Tsilimbaris, M.K., and Pallikaris, I.G. (2014). Combined topical application of a regenerative agent with a bandage contact lens for the treatment of persistent epithelial defects. Cornea 33, 868–872. - PDF
9- Maringe, E., Gueudry, J., Aifa, A., Delcampe, A., and Muraine, M. (2013). Topical treatment with a new matrix therapy agent (RGTA) in combination with limbal allograft in ocular surface desease and corneal anesthesia. Acta Ophthalmologica 91, 0–0.
10- Renault, D., Lazreg, S., and Abdellah, M.B.(2015) The use of matrix therapy in the treatment of corneal perforation. Invest. Ophthalmol. Vis. Sci. 56(7), 720–720.
11- Labetoulle, M., Rousseau, A., M’Garrech, M., Kaswin, G., Dupas, B., Baudouin, C., et al.(2014). Efficacy of heparin sulfate mimetic polymer in Cogan’s epithelial dystrophy. Invest. Ophthalmol. Vis. Sci. 55(13), 5519–5519.
12- Kymionis, G.D., Liakopoulos, D.A., Grentzelos, M.A., Tsoulnaras, K.I., Detorakis, E.T., Cochener, B., and Tsilimbaris, M.K. (2015). Effect of the Regenerative Agent Poly(Carboxymethylglucose Sulfate) on Corneal Wound Healing After Corneal Cross-Linking for Keratoconus. Cornea 34, 928–931. - PDF
13- Gumus, K., Guerra, M.G., de Melo Marques, S.H., Karaküçük, S., and Barritault, D. (2017). A New Matrix Therapy Agent for Faster Corneal Healing and Less Ocular Discomfort Following Epi-off Accelerated Corneal Cross-linking in Progressive Keratoconus. J Refract Surg 33, 163–170. - PDF
14- Bata, A.M., Witkowska, K.J., Wozniak, P.A., Fondi, K., Schmidinger, G., Pircher, N., Szegedi, S., Aranha dos Santos, V., Pantalon, A., Werkmeister, R.M., et al. (2016). Effect of a Matrix Therapy Agent on Corneal Epithelial Healing After Standard Collagen Cross-linking in Patients With Keratoconus: A Randomized Clinical Trial. JAMA Ophthalmology 134, 1169. - PDF